Menu Search
Equities

Cannara Biotech Inc

LOVFF:QBB

Cannara Biotech Inc

Actions
  • Price (USD)0.537
  • Today's Change0.00 / 0.00%
  • Shares traded5.50k
  • 1 Year change-13.41%
  • Beta--
Data delayed at least 15 minutes, as of May 09 2024 16:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company’s brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.

  • Revenue in CAD (TTM)73.38m
  • Net income in CAD6.22m
  • Incorporated2017
  • Employees--
  • Location
    Cannara Biotech IncSuite 2050 - 1055, West Georgia StreetVANCOUVER V6E 3P3CanadaCAN
  • Phone+1 (514) 913-9136
  • Fax+1 (514) 913-9136
  • Websitehttps://www.cannara.ca/en/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.